BAYER AG NA
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by Armin Schulz on June 26th, 2023 | 09:20 CEST
Bayer, BioNxt Solutions, BioNTech - Biotech facing a rebound?
Due to the Corona pandemic, the pharmaceutical and biotech sector received a lot of attention. Many investors invested too late and could hardly benefit from the significant upward movements. After the hype, a sense of disillusionment set in. The vaccine manufacturers felt the effects because as soon as the pandemic subsided, the stock market also went down. Large and small companies experienced sell-offs, with some trading below their cash reserves. These low prices led to a wave of takeovers. Most recently, Novartis snapped up the biotech company Chinook for up to USD 3.5 billion. Therefore, today, we look at three companies from the healthcare sector.
Read
Commented by Fabian Lorenz on June 7th, 2023 | 08:00 CEST
Commodity shares with price potential: Bayer, K+S, and Almonty Industries in the analyst check
There are no signs of a deep recession in the US at the moment, which is positive for commodity prices and the corresponding companies. What do analysts say? They see a price potential of over 170% for tungsten producer Almonty Industries. With the commissioning of the flagship mine in South Korea, revenues and profits should increase strongly from 2024. After K+S earned brilliantly last year, there is a lack of positive impulses this year. Several analysts have spoken out. Can the DAX-listed company make gains again? At Bayer, the euphoria surrounding the change in the board of directors has faded, and the share price is almost back to where it was at the beginning of the year. But analysts see significant upside potential.
Read
Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST
BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!
Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?
Read
Commented by Fabian Lorenz on May 3rd, 2023 | 07:30 CEST
Starting signal for a share price rally? BioNTech, Bayer, and BioNxt Solutions ahead of important dates
Things can move fast in the biotech sector. The share price of Prometheus Biosciences shot up by a good 75% practically overnight. The reason: US pharmaceutical group Merck & Co wants to buy the Company specializing in treating immune diseases, thus strengthening its own product portfolio. Thanks to clever takeovers, Sartorius has also grown strongly in recent years, become a success story on the German stock market and risen to the DAX. The latest acquisition of the laboratory supplier is Polyplus. The French company develops DNA and RNA components for cell and gene therapies. Is BioNxt, also active in Germany, the next takeover candidate? In any case, the Company is taking big steps towards commercialization. Investors are also hoping for new impetus from Bayer and BioNTech. Both companies have important dates coming up. But analysts are skeptical.
Read
Commented by André Will-Laudien on April 12th, 2023 | 10:34 CEST
Attention, biotech is back! Bayer, Defence Therapeutics, BioNTech - These stocks are breaking out!
For months the market did not care about biotech stocks. But now technical bottoms have been reached, and a rise is likely. In this context, the capital market interest rate is important: if it falls due to increased fears of recession, there is no stopping the biotechs because refinancing costs fall. Sentiment measurements over Easter showed that the risk bias of investors has also returned. If not now, then when, the moment is favorable! Shortlist the following stocks.
Read
Commented by Armin Schulz on April 5th, 2023 | 12:25 CEST
BioNTech, BioNxt Solutions, Bayer - The big one is only a matter of time
The biotech and pharmaceutical industry is currently in a constant state of flux, driven by the introduction of new technologies and the fight against global health problems. Producing medicines and therapies to alleviate diseases is of great value to people's health. Against the backdrop of an ageing population in industrialised nations, the sector will continue to be of great importance. A particular focus is on inventing advanced technologies to fight diseases such as cancer, Alzheimer's and Parkinson's. Today we look at three companies in the biotech and pharma sector.
Read
Commented by Nico Popp on April 4th, 2023 | 17:04 CEST
Race against cancer: BioNTech, Bayer, Defence Therapeutics
BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.
Read
Commented by Nico Popp on March 27th, 2023 | 09:26 CEST
Cost pressure in the healthcare system - how you benefit: Bayer, BioNxt, BioNTech
What do you think of the German healthcare system? While doctors regularly grumble about bureaucracy and patients about long waiting times or other inconsistencies, a new divide is opening up between pharmaceutical companies. Research-based pharmaceutical companies favour long patent protection, while generics manufacturers want more lax rules. We explain the system and highlight opportunities for investors.
Read
Commented by André Will-Laudien on March 15th, 2023 | 17:38 CET
Bayer, BioNxt, BioNTech - Biotech is on the rise again, bring on the blockbusters!
The time of the vaccine producers is over because the willingness to vaccinate is declining worldwide. As a result, the entire biotech sector has entered a strong correction phase since the pandemic mode for COVID-19 ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Complicating matters for companies is the significant increase in interest rates for long-term financing of their pipelines. When refinancing costs rise, this often leads to lower valuations. However, some companies are impressing with their innovations and have recently shown significant outperformance to the market. We evaluate the opportunities of some well-known biotech protagonists!
Read